Potentialities of nanomaterials for the management and treatment of metabolic syndrome: A new insight

Kassi, 2011, Metabolic syndrome: definitions and controversies, BMC Med., 9 Alberti, 2009, Harmonizing the metabolic syndrome, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 Saklayen, 2018, The global epidemic of the metabolic syndrome,, Curr. Hypertens. Rep., 20, 12, 10.1007/s11906-018-0812-z Rennie, 2003, Association of the metabolic syndrome with both vigorous and moderate physical activity, Int. J. Epidemiol., 32, 600, 10.1093/ije/dyg179 Bahadori, 1561, Recent advances in nanotechnology for the treatment of metabolic syndrome., Diabetes Metab, Syndr. 13 Davatgaran Taghipour, 2019, Nanoformulations of natural products for management of metabolic syndrome, Int. J. Nanomed., 14, 5303, 10.2147/IJN.S213831 Tsou, 2019, Nanotechnology-mediated drug delivery for the treatment of obesity and its related comorbidities, Adv. Healthc. Mater., 8, 1801184, 10.1002/adhm.201801184 Beuzelin, 2018, Exosomes and miRNA-loaded biomimetic nanovehicles, a focus on their potentials preventing type-2 diabetes linked to metabolic syndrome, front, Immunol., 9 Hiradate, 2021, A novel dual-targeted rosiglitazone-loaded nanoparticle for the prevention of diet-induced obesity via the browning of white adipose tissue,, J. Contr. Release, 329, 665, 10.1016/j.jconrel.2020.10.002 du Preez, 2019, Low-dose curcumin nanoparticles normalise blood pressure in male wistar rats with diet-induced metabolic syndrome, Nutrients, 11, 1542, 10.3390/nu11071542 Palmeiro-Silva, 2020, Effects of daily consumption of an aqueous dispersion of free-phytosterols nanoparticles on individuals with metabolic syndrome: a randomised, double-blind, placebo-controlled clinical trial,, Nutrients, 12, 2392, 10.3390/nu12082392 Nouri, 2020, Nanophytomedicines for the prevention of metabolic syndrome: a pharmacological and biopharmaceutical review, front. Bioeng, Biotechnol., 8 Furukawa, 2004, Increased oxidative stress in obesity and its impact on metabolic syndrome, J. Clin. Invest., 114, 1752, 10.1172/JCI21625 Rochlani, 2017, Metabolic syndrome: pathophysiology, management, and modulation by natural compounds, Ther. Adv. Cardiovasc. Dis, 11, 215, 10.1177/1753944717711379 Matsuzawa, 2011, The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism.,, J. Atherosclerosis Thromb., 18, 629, 10.5551/jat.7922 Tripathy, 2003, Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects, Diabetes, 52, 2882, 10.2337/diabetes.52.12.2882 Tooke, 2000, Adverse endothelial function and the insulin resistance syndrome, J. Intern. Med., 247, 425, 10.1046/j.1365-2796.2000.00671.x Wallace, 2001, Plasma leptin and the risk of cardiovascular disease in the west of scotland coronary prevention study (WOSCOPS), Circulation, 104, 3052, 10.1161/hc5001.101061 Lindsay, 2002, Adiponectin and development of type 2 diabetes in the Pima Indian population, Lancet, 360, 57, 10.1016/S0140-6736(02)09335-2 Mehta, 2007, Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system, Am, J. Physiol. Physiol, 292, C82, 10.1152/ajpcell.00287.2006 Gobal, 2011, Triad of metabolic syndrome, chronic kidney disease, and coronary heart disease with a focus on microalbuminuria, J. Am. Coll. Cardiol., 57, 2303, 10.1016/j.jacc.2011.02.027 Dai, 2013, LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells, Biochem. Biophys. Res. Commun., 437, 62, 10.1016/j.bbrc.2013.06.035 Hotamisligil, 1994, Tumor necrosis factor alpha inhibits signaling from the insulin receptor., Proc. Natl. Acad. Sci. U, S. A, 91, 4854 Tsigos, 1999, Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity, Metabolism, 48, 1332, 10.1016/S0026-0495(99)90277-9 Bastard, 2000, Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss∗, J. Clin. Endocrinol. Metab., 85, 3338 Wisse, 2004, The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity,, J. Am. Soc. Nephrol., 15, 2792, 10.1097/01.ASN.0000141966.69934.21 Naseri, 2018, Anthocyanins in the management of metabolic syndrome: a pharmacological and biopharmaceutical review, front, Pharmacol, 9 Gera, 2017, Nanoformulations of curcumin: an emerging paradigm for improved remedial application, Oncotarget, 8, 66680, 10.18632/oncotarget.19164 Pereira, 2018, Effect of nanoencapsulation using PLGA on antioxidant and antimicrobial activities of guabiroba fruit phenolic extract, Food Chem., 240, 396, 10.1016/j.foodchem.2017.07.144 Joshi, 2013, SNEDDS curcumin formulation leads to enhanced protection from pain and functional deficits associated with diabetic neuropathy: an insight into its mechanism for neuroprotection, Nanomedicine Nanotechnology, Biol, Med, 9, 776 Kim, 2014, Anti-obesity efficacy of nanoemulsion oleoresin capsicum in obese rats fed a high-fat diet, Int. J. Nanomed., 301 Kapoor, 2014, O-Hexadecyl-Dextran entrapped berberine nanoparticles abrogate high glucose stress induced apoptosis in primary rat hepatocytes, PLoS One, 9, e89124, 10.1371/journal.pone.0089124 Shi, 2016, Nanostructured lipid carriers loaded with baicalin: an efficient carrier for enhanced antidiabetic effects, Phcog. Mag., 12, 198, 10.4103/0973-1296.186347 Chitkara, 2012, Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model, Drug Deliv, Transl. Res., 2, 112 Lu, 2014, Preparation of a nano emodin transfersome and study on its anti-obesity mechanism in adipose tissue of diet-induced obese rats, J. Transl. Med, 12, 72 Ravichandran, 2012, Studies on gymnemic acids nanoparticulate formulations against diabetes mellitus, Int. J. Biomed. Clin. Eng., 1, 1, 10.4018/ijbce.2012070101 Pham, 2017, Nanodiamond enhances immune responses in mice against recombinant HA/H7N9 protein, J. Nanobiotechnol., 15, 69, 10.1186/s12951-017-0305-2 Yücel, 2018, Nanoliposomal resveratrol as a novel approach to treatment of diabetes mellitus, J. Nanosci. Nanotechnol., 18, 3856, 10.1166/jnn.2018.15247 Das, 2014, Engineered silybin nanoparticles educe efficient control in experimental diabetes, PLoS One, 9, e101818, 10.1371/journal.pone.0101818 Ahangarpour, 2018, Solid lipid nanoparticles of myricitrin have antioxidant and antidiabetic effects on streptozotocin-nicotinamide-induced diabetic model and myotube cell of male mouse, Oxid. Med. Cell. Longev, 2018, 1, 10.1155/2018/7496936 Barwal, 2013, Development of stevioside Pluronic-F-68 copolymer based PLA-nanoparticles as an antidiabetic nanomedicine, Colloids Surf. B Biointerfaces, 101, 510, 10.1016/j.colsurfb.2012.07.005 Paul, 2014, Comparative prophylactic effects of α-eleostearic acid rich nano and conventional emulsions in induced diabetic rats, J. Food Sci. Technol., 51, 1724, 10.1007/s13197-014-1257-2 González-Castejón, 2011, Dietary phytochemicals and their potential effects on obesity: a review,, Pharmacol. Res., 64, 438, 10.1016/j.phrs.2011.07.004 Tong, 2018, In vitro/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin/PBLG-PEG-PBLG nanoparticles, Int, J. Nanomedicine. Volume, 13, 1945 Jia, 2018, Nanoparticle-encapsulated curcumin inhibits diabetic neuropathic pain involving the P2Y12 receptor in the dorsal root ganglia, front, Neurosci, 11 Dwivedi Vinay, 2011, Ganguly chaiti, cytotoxic potential of Indian spices (extracts) against esophageal squamous carcinoma cells, Asian Pac. J. Cancer Prev. APJCP, 8, 2069 Allemand, 2016, Red pepper ( capsicum baccatum ) extracts present anti-inflammatory effects in vivo and inhibit the production of TNF-α and NO, Vitro, J. Med. Food, 19, 759, 10.1089/jmf.2015.0101 Li, 2017, Induction of apoptosis by berberine in hepatocellular carcinoma HepG2 cells via downregulation of NF-κB, Oncol. Res., 25, 233, 10.3727/096504016X14742891049073 Wang, 2015, Rhizoma as potential anticancer agents: recent updates and future perspectives, J. Ethnopharmacol., 176, 35, 10.1016/j.jep.2015.10.028 Bao, 2015, Hormetic effect of berberine attenuates the anticancer activity of chemotherapeutic agents, PLoS One, 10, e0139298, 10.1371/journal.pone.0139298 Yang, 2012, Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients, evidence-based complement. Altern, Med, 2012, 1 Ochin, 2018, Berberine encapsulated PLGA-PEG nanoparticles modulate PCSK-9 in HepG2 cells, Cardiovasc. Hematol. Disord. Targets, 18, 61, 10.2174/1871529X18666180201130340 Cavia-Saiz, 2010, Antioxidant properties, radical scavenging activity and biomolecule protection capacity of flavonoid naringenin and its glycoside naringin: a comparative study, J. Sci. Food Agric., 90, 1238, 10.1002/jsfa.3959 Ortiz-Andrade, 2008, Antidiabetic and toxicological evaluations of naringenin in normoglycaemic and NIDDM rat models and its implications on extra-pancreatic glucose regulation, Diabetes, Obes, Metab, 10, 1097 Renugadevi, 2009, Naringenin protects against cadmium-induced oxidative renal dysfunction in rats, Toxicology, 256, 128, 10.1016/j.tox.2008.11.012 Maity, 2017, Alginate coated chitosan core-shell nanoparticles for efficient oral delivery of naringenin in diabetic animals—an in vitro and in vivo approach, Carbohydr. Polym., 170, 124, 10.1016/j.carbpol.2017.04.066 Hashemzaei, 2017, Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo, Oncol. Rep., 38, 819, 10.3892/or.2017.5766 Rivera, 2008, Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese zucker rats, Obesity, 16, 2081, 10.1038/oby.2008.315 Mukhopadhyay, 2018, Preparation, characterization and in vivo evaluation of pH sensitive, safe quercetin-succinylated chitosan-alginate core-shell-corona nanoparticle for diabetes treatment, Carbohydr. Polym., 182, 42, 10.1016/j.carbpol.2017.10.098 Jayasuriya, 1992, Emodin, a protein tyrosine kinase inhibitor from polygonum cuspidatum, J. Nat. Prod., 55, 696, 10.1021/np50083a026 Dong, 2016, Emodin: a review of its pharmacology, toxicity and pharmacokinetics,, Phyther. Res., 30, 1207, 10.1002/ptr.5631 Li, 2017, Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia, Purinergic Signal., 13, 559, 10.1007/s11302-017-9583-2 Saneja Ankit, 2009, Gymnema sylvestre (gurmar): a review,, Der Pharm. Lett., 2 Waisundara, 2009, Baicalin improves antioxidant status of streptozotocin-induced diabetic wistar rats, J. Agric. Food Chem., 57, 4096, 10.1021/jf8028539 Dinda, 2017, Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders, Eur. J. Med. Chem., 131, 68, 10.1016/j.ejmech.2017.03.004 Xiong, 2006, Determination of scutellarin in mouse plasma and different tissues by high-performance liquid chromatography, J. Chromatogr. B., 835, 114, 10.1016/j.jchromb.2006.02.041 Zheng, 2015, Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies,, BioMed Res. Int., 2015, 1 Rosen, 2014, What we talk about when we talk about fat, Cell, 156, 20, 10.1016/j.cell.2013.12.012 Rytka, 2011, The portal theory supported by venous drainage–selective fat transplantation,, Diabetes, 60, 56, 10.2337/db10-0697 Geurts, 2014, Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics, Benef. Microbes, 5, 3, 10.3920/BM2012.0065 Hersoug, 2016, Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity, Obes. Rev., 17, 297, 10.1111/obr.12370 Hersoug, 2018, Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity, Nutr. Res. Rev., 31, 153, 10.1017/S0954422417000269 Méndez-del Villar, 2014, Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion, Metab. Syndr. Relat. Disord., 12, 497, 10.1089/met.2014.0082 Yu, 2012, Cellular and molecular effects of resveratrol in health and disease, J. Cell. Biochem., 113, 752, 10.1002/jcb.23431 Shahraki, 2017, Resveratrol nano-capsule as an effi cient tool for blood pressure regulation: a study on metabolic syndrome induced mice, Biosci, Biotechnol. Res. Commun, 10, 623, 10.21786/bbrc/10.4/4 Hoh, 2007, Quantitation of silibinin, a putative cancer chemopreventive agent derived from milk thistle ( Silybum marianum ), in human plasma by high-performance liquid chromatography and identification of possible metabolites, J. Agric. Food Chem., 55, 2532, 10.1021/jf063156c Tajmohammadi, 2018, Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: a review,, Phyther. Res., 32, 1933, 10.1002/ptr.6153 Pereira, 2011, Myricitrin, a nitric oxide and protein kinase C inhibitor, exerts antipsychotic-like effects in animal models, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 35, 1636, 10.1016/j.pnpbp.2011.06.002 Sun, 2013, Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE−/− mice, Toxicol. Appl. Pharmacol., 271, 114, 10.1016/j.taap.2013.04.015 Goyal Essential Oils in Food Preservation, 2016 Kumar, 2021, Experimental and computational study of naphthalimide derivatives: synthesis, optical, nonlinear optical and antiviral properties, Optik, 246, 167748, 10.1016/j.ijleo.2021.167748 Kumar, 2020, Substituted phenothiazines: synthesis and in silico evaluation of D4 dopamine receptor inhibition, SN Appl. Sci, 2, 1241, 10.1007/s42452-020-3067-7 Singh, 2012, A novel ternary NiFe2O4/CuO/FeO-chitosan nanocomposite as a cholesterol biosensor,, Process Biochem., 47, 2189, 10.1016/j.procbio.2012.08.012 Upadhyaya, 2013, Biomedical applications of carboxymethyl chitosans, Carbohydr. Polym., 91, 452, 10.1016/j.carbpol.2012.07.076 Singh, 2021, 1 Fernandes, 2020, Recent applications of magnesium oxide (MgO) nanoparticles in various domains, Adv. Mater. Lett., 11, 10.5185/amlett.2020.081543 Singh, 2012, 215 Singh, 2014, 141 Singh, 2021, Introduction to bionanomaterials: an overview, in: Bionanomaterials, IOP Publishing Singh, 2021 Adetunji, 2021, 129 Singh, 2020, Cerium oxide nanoparticles: properties, biosynthesis and biomedical application, RSC Adv., 10, 27194, 10.1039/D0RA04736H Nayak, 2021, Potentialities of selenium nanoparticles in biomedical science, New J. Chem., 45, 2849, 10.1039/D0NJ05884J Singh, 2020, Potential applications of peptide nucleic acid in biomedical domain, Eng, Report Souto, 2019, Nanoparticle delivery systems in the treatment of diabetes complications, Molecules, 24, 4209, 10.3390/molecules24234209 Wong, 2017, Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment, J. Contr. Release, 264, 247, 10.1016/j.jconrel.2017.09.003 Kesharwani, 2018, Nanotechnology based approaches for anti-diabetic drugs delivery, Diabetes Res. Clin. Pract., 136, 52, 10.1016/j.diabres.2017.11.018 Wong, 2016, Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities, J. Pharm. Pharmacol., 68, 1093, 10.1111/jphp.12607 Neef, 2017, Tolerogenic nanoparticles to treat islet autoimmunity, Curr. Diabetes Rep., 17, 84, 10.1007/s11892-017-0914-z Veiseh, 2015, Managing diabetes with nanomedicine: challenges and opportunities, Nat. Rev. Drug Discov., 14, 45, 10.1038/nrd4477 Ismail, 2017, Novel strategies in the oral delivery of antidiabetic peptide drugs – insulin, GLP 1 and its analogs, Eur, J. Pharmacokinet. Biopharm., 115, 257, 10.1016/j.ejpb.2017.03.015 Lin, 2017, Recent advances in oral delivery of drugs and bioactive natural products using solid lipid nanoparticles as the carriers, J. Food Drug Anal., 25, 219, 10.1016/j.jfda.2017.02.001 Bahman, 2019, Nanotechnology in insulin delivery for management of diabetes, pharm, Nanotechnology, 7, 113 Mohsen, 2019, Nanotechnology advanced strategies for the management of diabetes mellitus, curr, Drug Targets, 20, 995, 10.2174/1389450120666190307101642 Mansoor, 2019, Polymer-based nanoparticle strategies for insulin delivery, Polymers, 11, 1380, 10.3390/polym11091380 Ganesan, 2017, Phytobioactive compound-based nanodelivery systems for the treatment of type 2 diabetes mellitus – current status, Int. J. Nanomedicine. Volume, 12, 1097, 10.2147/IJN.S124601 Zheng, 2018, Global aetiology and epidemiology of type 2 diabetes mellitus and its complications, Nat. Rev. Endocrinol., 14, 88, 10.1038/nrendo.2017.151 Cerf, 2013, Endocrinol. (Lausanne), 4 Jaiswal, 2021, Chitosan modified by organo-functionalities as an efficient nanoplatform for anti-cancer drug delivery process, J. Drug Deliv. Sci. Technol., 62, 102407, 10.1016/j.jddst.2021.102407 Li, 2013, Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles, Biomaterials, 34, 9678, 10.1016/j.biomaterials.2013.08.048 Elsayed, 2009, Formulation and characterization of an oily-based system for oral delivery of insulin, Eur, J. Pharmacokinet. Biopharm., 73, 269, 10.1016/j.ejpb.2009.06.004 Chuang, 2013, Calcium depletion-mediated protease inhibition and apical-junctional-complex disassembly via an EGTA-conjugated carrier for oral insulin delivery, J. Contr. Release, 169, 296, 10.1016/j.jconrel.2012.11.011 Lin, 2007, Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery, Biomacromolecules, 8, 146, 10.1021/bm0607776 Mi, 2008, Oral delivery of peptide drugs using nanoparticles self-assembled by poly(γ-glutamic acid) and a chitosan derivative functionalized by trimethylation, Bioconjugate Chem., 19, 1248, 10.1021/bc800076n Thanou, 2001, Oral drug absorption enhancement by chitosan and its derivatives, Adv. Drug Deliv. Rev., 52, 117, 10.1016/S0169-409X(01)00231-9 George, 2006, Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan — a review, J. Contr. Release, 114, 1, 10.1016/j.jconrel.2006.04.017 Gombotz, 1998, Protein release from alginate matrices, Adv. Drug Deliv. Rev., 31, 267, 10.1016/S0169-409X(97)00124-5 Tahtat, 2013, Oral delivery of insulin from alginate/chitosan crosslinked by glutaraldehyde, Int. J. Biol. Macromol., 58, 160, 10.1016/j.ijbiomac.2013.03.064 Zhang, 2010, Effective protection and controlled release of insulin by cationic beta-cyclodextrin polymers from alginate/chitosan nanoparticles, Int. J. Pharm., 393, 212, 10.1016/j.ijpharm.2010.04.006 Hu, 2018, Recent advances of polysaccharide-based nanoparticles for oral insulin delivery, Int. J. Biol. Macromol., 120, 775, 10.1016/j.ijbiomac.2018.08.152 Cui, 2011, Hydrophobic ion pairing of an insulin-sodium deoxycholate complex for oral delivery of insulin, Int. J. Nanomed., 3049 Sun, 2008, A novel insulin-sodium oleate complex for oral administration: preparation, characterization and in vivo evaluation,, J. Drug Deliv. Sci. Technol., 18, 239, 10.1016/S1773-2247(08)50047-5 Sun, 2010, Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation, J. Microencapsul., 27, 471, 10.3109/02652040903515490 Zhang, 2012, Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration, Eur. J. Pharmaceut. Sci., 45, 632, 10.1016/j.ejps.2012.01.002 Jain, 2012, Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin, Nanomedicine, 7, 1311, 10.2217/nnm.12.31 Kamei, 2008, Usefulness of cell-penetrating peptides to improve intestinal insulin absorption, J. Contr. Release, 132, 21, 10.1016/j.jconrel.2008.08.001 Zhu, 2016, Polymeric nanoparticles amenable to simultaneous installation of exterior targeting and interior therapeutic proteins, Angew. Chem. Int. Ed., 55, 3309, 10.1002/anie.201509183 Shan, 2016, Enhanced oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers, ACS, Appl. Mater. Interfaces, 8, 25444, 10.1021/acsami.6b08183 Hasan, 2013, Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system, Drug Deliv., 20, 120, 10.3109/10717544.2013.779332 Labieniec-Watala, 2014, Can metabolic impairments in experimental diabetes be cured with poly(amido)amine (PAMAM) G4 dendrimers? – in the search for minimizing of the adverse effects of PAMAM administration, Int. J. Pharm., 464, 152, 10.1016/j.ijpharm.2014.01.011 Li, 2015, Glucose-responsive micelles for insulin release, J. Contr. Release, 213, e122, 10.1016/j.jconrel.2015.05.206 Yang, 2013, Glucose-responsive complex micelles for self-regulated release of insulin under physiological conditions, Soft Matter, 9, 8589, 10.1039/c3sm51538a Joshi, 2006, Gold nanoparticles as carriers for efficient transmucosal insulin delivery, Langmuir, 22, 300, 10.1021/la051982u Cho, 2014, Chondroitin sulfate-capped gold nanoparticles for the oral delivery of insulin, Int. J. Biol. Macromol., 63, 15, 10.1016/j.ijbiomac.2013.10.026 Zhao, 2013, Preparation, characterization, and evaluation in vivo of Ins-SiO2-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin, Int. J. Pharm., 454, 278, 10.1016/j.ijpharm.2013.06.051 Boushra, 2016, Methocel-lipid hybrid nanocarrier for efficient oral insulin delivery, J. Pharmacol. Sci., 105, 1733, 10.1016/j.xphs.2016.02.018 Boushra, 2016, Development and evaluation of viscosity-enhanced nanocarrier (VEN) for oral insulin delivery, Int. J. Pharm., 511, 462, 10.1016/j.ijpharm.2016.07.016 Lv Hui-Xia, 2012, Solid lipid nanoparticles modified with stearic acid–octaarginine for oral administration of insulin, Int. J. Nanomed., 3333 Lauby-Secretan, 2016, Body fatness and cancer — viewpoint of the IARC working group, N. Engl, J. Med., 375, 794 Bouchard, 2010, Defining the genetic architecture of the predisposition to obesity: a challenging but not insurmountable task, Am, J. Clin. Nutr., 91, 5 Speakman, 2006, Thrifty genes for obesity and the metabolic syndrome — time to call off the search?, Diabetes Vasc, Dis. Res., 3, 7 Tsou, 2019, Nanotechnology-mediated drug delivery for the treatment of obesity and its related comorbidities, Adv. Healthc. Mater., 8, 1801184, 10.1002/adhm.201801184 Cordero, 2015, Epigenetics of obesity, Curr. Opin. Clin. Nutr. Metab. Care, 18, 361, 10.1097/MCO.0000000000000179 Gadde, 2018, Obesity, J. Am. Coll. Cardiol., 71, 69, 10.1016/j.jacc.2017.11.011 Yameen, 2014, Insight into nanoparticle cellular uptake and intracellular targeting, J. Contr. Release, 190, 485, 10.1016/j.jconrel.2014.06.038 Huang, 2019, Polymeric carriers for controlled drug delivery in obesity treatment, trends Endocrinol, Metab, 30, 974 Vishvanath, 2019, Contribution of adipogenesis to healthy adipose tissue expansion in obesity, J. Clin. Invest., 129, 4022, 10.1172/JCI129191 Neumann, 2016, Adipokines in bone disease, Nat. Rev. Rheumatol., 12, 296, 10.1038/nrrheum.2016.49 Ouchi, 2011, Adipokines in inflammation and metabolic disease, Nat. Rev. Immunol., 11, 85, 10.1038/nri2921 Rocca, 2015, Pilot in vivo investigation of cerium oxide nanoparticles as a novel anti-obesity pharmaceutical formulation, Nanomedicine, 11, 1725, 10.1016/j.nano.2015.05.001 Zu, 2018, Resveratrol liposomes and lipid nanocarriers: comparison of characteristics and inducing browning of white adipocytes, Colloids Surf. B Biointerfaces, 164, 414, 10.1016/j.colsurfb.2017.12.044 Yekollu, 2011, Targeting curcusomes to inflammatory dendritic cells inhibits NF-κB and improves insulin resistance in obese mice, Diabetes, 60, 2928, 10.2337/db11-0275 Jiang, 2017, Dibenzazepine-loaded nanoparticles induce local browning of white adipose tissue to counteract obesity, mol, Therapy, 25, 1718 Sibuyi, 2019, Nanotechnology advances towards development of targeted-treatment for obesity, J. Nanobiotechnol., 17, 122, 10.1186/s12951-019-0554-3 de Raad, 2014, Peptide vectors for gene delivery: from single peptides to multifunctional peptide nanocarriers, Nanomedicine, 9, 2217, 10.2217/nnm.14.90 Won, 2014, Oligopeptide complex for targeted non-viral gene delivery to adipocytes, Nat. Mater., 13, 1157, 10.1038/nmat4092 Kolovou, 2005, Pathophysiology of dyslipidaemia in the metabolic syndrome, Postgrad. Med., 81, 358, 10.1136/pgmj.2004.025601 Klop, 2013, Dyslipidemia in obesity: mechanisms and potential targets, Nutrients, 5, 1218, 10.3390/nu5041218 Ginsberg, 2006, Metabolic syndrome: focus on dyslipidemia, Obesity, 14, 41S, 10.1038/oby.2006.281 Iqbal, 2018, Metabolic syndrome, dyslipidemia and regulation of lipoprotein metabolism, Curr. Diabetes Rev., 14, 427, 10.2174/1573399813666170705161039 Veilleux, 2014, É. Grenier, P. Marceau, A.C. Carpentier, D. Richard, E. Levy, intestinal lipid handling, Arterioscler. Thromb. Vasc. Biol., 34, 644, 10.1161/ATVBAHA.113.302993 Sadur, 1984, Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity∗, J. Clin. Endocrinol. Metab., 59, 1176, 10.1210/jcem-59-6-1176 Bergman, 2007, Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk, Am. J. Med., 120, S3, 10.1016/j.amjmed.2006.11.012 Tamura, 2005, Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease, J. Clin. Invest., 115, 1139, 10.1172/JCI24930 Barrows, 2006, Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states, J. Clin. Endocrinol. Metab., 91, 1446, 10.1210/jc.2005-1709 Adiels, 2008, Overproduction of very low–density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome, Arterioscler. Thromb. Vasc. Biol., 28, 1225, 10.1161/ATVBAHA.107.160192 Wetterau, 1992, Gregg, Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia, Science (80-. ), 258, 999, 10.1126/science.1439810 Lamarche, 1997, Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men, Circulation, 95, 69, 10.1161/01.CIR.95.1.69 Gardner, 1996, Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women, J. Am. Med. Assoc., 276, 875, 10.1001/jama.1996.03540110029028 Rashid, 2003, Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity, Clin. Biochem., 36, 421, 10.1016/S0009-9120(03)00078-X Drew, 2012, The emerging role of HDL in glucose metabolism,, Nat. Rev. Endocrinol., 8, 237, 10.1038/nrendo.2011.235 Masuda, 2017, Atheroscler. Thromb, 24, 95, 10.5551/jat.RV16003 Ferri, 2016, Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia, Endocrine, 54, 588, 10.1007/s12020-016-0939-0 Zhang, 2007, Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation, J. Biol. Chem., 282, 18602, 10.1074/jbc.M702027200 Tatò, 1998, Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase 11This work was supported in part by grants HL-29252 and HL-22682 from the department of veterans affa, Am. J. Cardiol., 81, 805, 10.1016/S0002-9149(97)01016-3 Rubic, 2004, Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin, Biochem, Pharmacol, 67, 411 Staels, 1998, Regulation of apo A-I gene expression by fibrates, Atherosclerosis, 137, S19, 10.1016/S0021-9150(97)00313-4 Sharma, 2016, Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia, Drug Deliv., 23, 684, 10.3109/10717544.2014.920937 Shepherd, 1989, Mechanism of action of bile acid sequestrants and other lipid-lowering drugs, Cardiology, 76, 65, 10.1159/000174548 Meena, 2008, Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure® in treating hyperlipidemia, Lipids, 43, 231, 10.1007/s11745-007-3142-5 Sathali, 2013, A.H, development of solid lipid nanoparticles of rosuvastatin calcium, BioMed Res. Int., 1, 536 Ansari, 2011, Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study, AAPS, PharmSciTech, 12, 279, 10.1208/s12249-011-9584-3 Lee Chung, 2015, Nanomedicines for endothelial disorders, Nano Today, 10, 759, 10.1016/j.nantod.2015.11.009 Cines, 1998, Endothelial cells in physiology and in the pathophysiology of vascular disorders, Blood, 91, 3527 Luo, 2007, Structural basis of integrin regulation and signaling, Annu. Rev. Immunol., 25, 619, 10.1146/annurev.immunol.25.022106.141618 Brown, 2000, Blood-brain barrier function in cerebral malaria and CNS infections in Vietnam, Neurology, 55, 104, 10.1212/WNL.55.1.104 Nakamura, 2012, Changes in the retina after chronic oxygen-induced retinopathy, PLoS One, 7, e32167, 10.1371/journal.pone.0032167 Stirban, 2006, Dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes, Diabetes Care, 29, 2064, 10.2337/dc06-0531 Rajendran, 2013, The vascular endothelium and human diseases, Int, J. Biol. Sci., 9, 1057 Hori, 2008, Oxidative stress and left ventricular remodelling after myocardial infarction, Cardiovasc. Res., 81, 457, 10.1093/cvr/cvn335 Libby, 2006, Inflammation and cardiovascular disease mechanisms, Am, J. Clin. Nutr., 83, 456S Golomb, 2008, Statin adverse effects, Am, J. Cardiovasc. Drugs, 8, 373, 10.2165/0129784-200808060-00004 Shafiq, 2008, Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug, Am. J. Med., 121, 265, 10.1016/j.amjmed.2007.11.016 Snima, 2012, O-Carboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells, Carbohydr. Polym., 89, 1003, 10.1016/j.carbpol.2012.04.050 Ghosh, 2012, Polymeric nanomaterials for islet targeting and immunotherapeutic delivery, Nano Lett., 12, 203, 10.1021/nl203334c Lobatto, 2010, Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis, mol, Pharm. Times, 7, 2020 Chan, 2011, In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles, Proc. Natl. Acad. Sci. Unit. States Am., 108, 19347, 10.1073/pnas.1115945108 Klingenberg, 2009, Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies, Eur. Heart J., 30, 2838, 10.1093/eurheartj/ehp477 Kamaly, 2013, Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles, Proc. Natl. Acad. Sci. Unit. States Am., 110, 6506, 10.1073/pnas.1303377110 Shaw, 2008, Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque, Circ. Res., 103, 1084, 10.1161/CIRCRESAHA.108.182063 Younossi, 2019, Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Hepatology, 69, 2672, 10.1002/hep.30251 Chao, 2019, Homeostasis of glucose and lipid in non-alcoholic fatty liver disease, Int. J. Mol. Sci, 20, 298 Zhao, 2020, Rapamycin-loaded mPEG-PLGA nanoparticles ameliorate hepatic steatosis and liver injury in non-alcoholic fatty liver disease, Front. Chem., 8, 10.3389/fchem.2020.00407 Shi, 2020, Nonalcoholic fatty liver disease: pathogenesis and treatment in traditional Chinese medicine and western medicine, evidence-based complement. Altern, Med, 2020, 1 Vreman, 2017, Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model, BMJ Open, 7, e013543, 10.1136/bmjopen-2016-013543 Jung, 2014, The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease, Int, J. Mol. Sci., 15, 6184, 10.3390/ijms15046184 Day, 2006, From fat to inflammation, Gastroenterology, 130, 207, 10.1053/j.gastro.2005.11.017 Day, 1998, Steatohepatitis: a tale of two “hits”?,, Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2 Tilg, 2010, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis,, Hepatology, 52, 1836, 10.1002/hep.24001 T, 2001, Am. Med. Assoc., 285, 2486, 10.1001/jama.285.19.2486 Pagano, 2002, Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association, Hepatology, 35, 367, 10.1053/jhep.2002.30690 Hamaguchi, 2005, The metabolic syndrome as a predictor of nonalcoholic fatty liver disease, ann. Intern. Med, 143, 722 Lomonaco, 2012, Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease, Hepatology, 55, 1389, 10.1002/hep.25539 Petersen, 2017, Roles of diacylglycerols and ceramides in hepatic insulin resistance, Trends Pharmacol. Sci., 38, 649, 10.1016/j.tips.2017.04.004 Gastaldelli, 2007, Resistance in nondiabetic and type 2 diabetic subjects, Gastroenterology, 133, 496, 10.1053/j.gastro.2007.04.068 Brown, 2008, Selective versus total insulin resistance: a pathogenic paradox,, Cell Metabol., 7, 95, 10.1016/j.cmet.2007.12.009 Cohen, 2006, The twentieth century struggle to decipher insulin signalling,, Nat. Rev. Mol. Cell Biol., 7, 867, 10.1038/nrm2043 Dongiovanni, 2010, Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease, Gut, 59, 267, 10.1136/gut.2009.190801 Jacome-Sosa, 2014, Fatty acid sources and their fluxes as they contribute to plasma triglyceride concentrations and fatty liver in humans, Curr. Opin. Lipidol., 25, 213, 10.1097/MOL.0000000000000080 Chiang, 2011, Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults, Cardiovasc. Diabetol., 10, 93, 10.1186/1475-2840-10-93 Schwarz, 2003, Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets, Am, J. Clin. Nutr., 77, 43 Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat. Genet., 40, 1461, 10.1038/ng.257 Wan, 2018, Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy, R. Soc. Open Sci, 5, 181457 Li, 2019, Mixed micelles loaded with the 5-benzylidenethiazolidine-2,4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis, Int. J. Nanomedicine. Volume, 14, 3943, 10.2147/IJN.S202821 Bai, 2020, Recent advances in nanomedicine for the diagnosis and therapy of liver fibrosis, Nanomaterials, 10, 1945, 10.3390/nano10101945 Oró, 2016, Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis, J. Hepatol., 64, 691, 10.1016/j.jhep.2015.10.020 Rani, 2018, Zinc oxide nanoparticles inhibit dimethylnitrosamine induced liver injury in rat, Chem. Biol. Interact., 295, 84, 10.1016/j.cbi.2017.10.009 Fan, 2020, Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy, Biomaterials, 230, 119616, 10.1016/j.biomaterials.2019.119616 Reebye, 2018, Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer, Oncogene, 37, 3216, 10.1038/s41388-018-0126-2 Jiménez Calvente, 2015, Specific hepatic delivery of procollagen α1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis, Hepatology, 62, 1285, 10.1002/hep.27936 El-Mezayen, 2017, Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: a novel strategy with potent efficacy in experimental liver fibrosis,, J. Contr. Release, 266, 226, 10.1016/j.jconrel.2017.09.035 Wu, 2019, Synergistic MicroRNA therapy in liver fibrotic rat using MRI-visible nanocarrier targeting hepatic stellate cells, Adv. Sci., 6, 1801809, 10.1002/advs.201801809 Leber, 2017, SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles, J. Contr. Release, 248, 10, 10.1016/j.jconrel.2016.12.006 Vivero-Escoto, 2019, Nanoparticle mediated silencing of tenascin C in hepatic stellate cells: effect on inflammatory gene expression and cell migration, J. Mater. Chem. B, 7, 7396, 10.1039/C9TB01845J Algandaby, 2016, Curcumin-zein nanospheres improve liver targeting and antifibrotic activity of curcumin in carbon tetrachloride-induced mice liver fibrosis, J. Biomed. Nanotechnol., 12, 1746, 10.1166/jbn.2016.2270 Lam, 2015, Evaluation of berberine/bovine serum albumin nanoparticles for liver fibrosis therapy, Green Chem., 17, 1640, 10.1039/C4GC01815J Violatto, 2019, Dexamethasone conjugation to biodegradable avidin-nucleic-acid-nano-assemblies promotes selective liver targeting and improves therapeutic efficacy in an autoimmune hepatitis murine model, ACS Nano, 13, 4410, 10.1021/acsnano.8b09655 Qiao, 2018, Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis, J. Contr. Release, 283, 113, 10.1016/j.jconrel.2018.05.032 Hassan, 2019, Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis, Eur, J. Pharmacokinet. Biopharm., 134, 96, 10.1016/j.ejpb.2018.11.018 Morsy, 2018, Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers, Int. J. Pharm., 552, 241, 10.1016/j.ijpharm.2018.10.003 Bahadori, 2019, Recent advances in nanotechnology for the treatment of metabolic syndrome, Diabetes Metab. Syndr. Clin. Res. Rev., 13, 1561, 10.1016/j.dsx.2019.03.002 Castro-Barquero, 2020, Dietary strategies for metabolic syndrome: a comprehensive review,, Nutrients, 12, 2983, 10.3390/nu12102983 Cefalu, 2015, Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors' expert forum, Diabetes Care, 38, 1567, 10.2337/dc15-1081 Bobo, 2016, Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date,, Pharm. Res. (N. Y.), 33, 2373, 10.1007/s11095-016-1958-5